BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 25379460)

  • 1. Steroid hormone synthetic pathways in prostate cancer.
    Mostaghel EA
    Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
    Mostaghel EA
    Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
    Mostaghel EA
    Cancer Manag Res; 2014; 6():39-51. PubMed ID: 24501545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
    Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
    Mostaghel EA; Solomon KR; Pelton K; Freeman MR; Montgomery RB
    PLoS One; 2012; 7(1):e30062. PubMed ID: 22279565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
    Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
    Locke JA; Nelson CC; Adomat HH; Hendy SC; Gleave ME; Guns ES
    J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):126-36. PubMed ID: 19442514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
    Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.
    Zhang A; Zhang J; Plymate S; Mostaghel EA
    Horm Cancer; 2016 Apr; 7(2):104-13. PubMed ID: 26797685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
    Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
    Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
    Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
    Lubik AA; Nouri M; Truong S; Ghaffari M; Adomat HH; Corey E; Cox ME; Li N; Guns ES; Yenki P; Pham S; Buttyan R
    Int J Cancer; 2017 Jan; 140(2):358-369. PubMed ID: 27672740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
    Cai C; Balk SP
    Endocr Relat Cancer; 2011 Oct; 18(5):R175-82. PubMed ID: 21712345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.